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1. Introduction 
Pentapeptides, Metenkephalin (ENK) and Leu- 
ENK [l] with opiate agonist activity produce only 
weak and short-lived analgesia even after intracere- 
broventricular (i.c.v.) administration [2,3] and no 
analgesia follows their subcutaneous (s.c.) administra- 
tion. This is due to their rapid enzymatic degradation, 
and various attempts have been made to obtain ENK 
derivatives with high and prolonged analgesic activity 
by protecting the N- and C-terminals and the peptide 
bond of the molecule [4]. 
in SD-20 also produce analgesia after S.C. administra- 
tion [8]. These findings indicate that all 5 amino acids 
in ENK are not necessary for S.C. analgesic activity. 
We therefore sought the ‘minimal segment’ of 
ENK required for S.C. analgesia and could find a tri- 
peptide alkylamide with S.C. analgesia [ 121. Here, we 
report the synthesis of a simple tripeptide Tyr-D 
Met(O)-Gly-MPA named ‘syndyphalin (SD)33’ 
(fig.1) which exhibits potent opioid activity in vitro 
2 (OMe) -Gly 
1 NDPP 
In [5-71, we reported that [MeTyr’,Metol’]-ENK 
(SD-6) and [MeTyr’,D-Ala2,Metols]-ENK (SD14) 
have high and prolonged opioid activity in vitro and 
analgesia after i.c.v. administration. SD-6, however, 
produces only weak analgesia after S.C. administration 
[8]. This discrepancy might be due to its difficulty to 
cross the blood-brain barrier and/or its rapid degra- 
dation by endopeptidases [4]. 
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Short-chain ENK analogues Tyr-DAla-Gly- 
alkylamides and Tyr-D-Ala-Gly-Pheol (SD-l 3) 
have opioid activities in vitro but do not show any 
significant analgesia after systemic administration 
[6-l 11. Tyr-D-Met(O)-Gly-Pheol (SD-20) and 
Tyr-D-Met(O)-Gly-MePheol (SD-25) exhibit high 
and prolonged analgesia after S.C. administration [ 111, 
and the acetylated derivatives of the hydroxyl group 
Boc-Tyr-D-Met (0) -N2H3 
?I 
Boc-Tyr-D-Met (0) -Gly-MPA (2) 
1 TFA 
OH CH, 
Abbreviations: MeTyr, N-methyl-L-tyrosine; Metol, L-methi- 
oninol; Pheol, L-phenylalaninol; D-Met(O), D-methionine 
sulfoxide; MePheol, N-methyl-L-phenylalaninol; MPA, N- 
methylphenethylamide; PA, phenethylamide; Z(OMe), 
p-methoxybenzyloxycarbonyl; NDPP, norborn-5ene-2,3- 
dicarboximido diphenyl phosphate; TFA, trifluoroacetic 
acid; Boc, t-butoxycarbonyl 
CH 
12 CH2 ‘;’ fH2 
(Tyr -D-Met (0) -Gly -MPA) 
Fig.1. Synthetic scheme and structural formula of SD-33. 
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and analgesia after s.c. administration. SD-33 is the 
only tripeptide alkylamide xhibiting substantial 
analgesia fter s.c. administration. 
2. Experimental 
2.1. Syntheses ofpeptides 
Tripeptide alkylamides were chemically synthesized 
as in [5,6,11]. Thin-layer chromatograms were run on 
Merck silica gel 60 F-254 pre-coated plates (0.25 mm). 
R F ] andRF 2 values refer to the systems of chloroform- 
methanol-water (8:3:1, lower layer) and n-butanol -  
acetic acid-water (3:1:1), respectively. 
2.1.1. Synthesis of Tyr-D-Met(O)-Gly-MPA 
(SD-33) 
The synthetic scheme is outlined in rigA. Z(OMe)- 
Gly and N-methylphenethylamine were condensed 
using NDPP [ 13] in the presence of triethylamine in 
ethyl acetate. After the coupling reaction for 24 h at 
room temperature, Z(OMe)-Gly-MPA (1) was 
obtained in 93% yield (m.p. 77 -78°C;RF  1 0.85; 
satisfactory elemental nalysis for C2oH2404N2). 
Compound 1 was deblocked with TFA-anisole, 
and the resulting Gly-MPA was condensed with 
Boc-Tyr-D-Met(O)-N2H3 [ 11 ] by the azide method 
in dimethylformamide. After the coupling reaction 
for 48 h at 4°C, Boc-Tyr -D-Met(O)-Gly-MPA (2) 
was obtained in 69%yield (m.p. 116-118°C;RF ~ 0.79; 
satisfactory analysis for C3oH42OTN4S •1.5 H20). 
Compound 2 was deblocked with TFA-anisole, 
and the deblocked material was converted to the ace- 
tate form by the treatment with Ambeflite IRA-400 
(acetate cycle). This solid material was reprecipitated 
from methanol-ethyl  acetate, and Tyr-D-Met(O)-  
Table 1 
Opioid activity on guinea pig ileum and analgesic activities in mice after 
s.c. administration 
Compound Effect on the isolated guinea pig ileum 
EDso [M] Relative 
(mean +_ SEM) potency a 
Morphine •HC1 
Tyr-Gly-Gly-Phe-Met (Met-ENK) 
Tyr-D-Met(O)-GIy-PA (SD-32) 
Tyr-D-Met(O)-GIy-MPA (SD-33) 
5.24 +- 0.63 × 10 -8 (n = 37) b 1.00 
3.35 -+ 1.17 × 10 -8 (n = 21) 1.56 
6.16 ± 1.49 × 10 -9 (n = 6) 8.51 
4.66 +- 1.53 × 10 -9 (n = 6) 11.24 
Analgesic activity in the tail flick test 
EDso [mg/kg, s.c. l Relative 
(95% confidence limits) potency a 
Morphine •HC1 
Tyr-Gly-Gly-Phe-Met (Met-ENK) 
Tyr-D-Met(O)-Gly-PA (SD-32) 
Tyr-D-Met(O)-GIy-MPA (SD-33) 
2.55 (1.81-3.58) (n = 30) 1.00 
>80 (n = 5) - 
>80 (n = 25) - 
4.04 (2.67-7.21) (n = 39) 1.14 
Analgesic activity in the writhing test 
EDso [mg/kg, s.c.] Relative 
(95% confidence limits) potency a 
Morphine •HCI 
Tyr-Gly-Gly-Phe-Met (Met-ENK) 
Tyr-D-Met(O)-GIy-PA (SD-32) 
Tyr-D-Met(O)-Gly-MPA (SD-33) 
0.500 (0.315-0.794) (n = 18) 1.00 
>25 (n = 5) - 
>10 (n = 20) 0.09_2 
0.801 (0.374-1.72) (n = 25) 1.13 
a Relative potency is on a molar basis (morphine = 1.00) 
b n = number of experiments ormice used 
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Gly-MPA (SD-33) was obtained as the acetate form 
in 89%yield (m.p. I40-I44”C;RF’ 0.25,RF’ 0.32; 
satisfactory analysis for CzsH3405N4S . CHJCOzH . 
H20). 
2.1.2. Synthesis of Tyr-D-Met(O)-Gly-PA (SD-32) 
SD-32 was synthesized by the same method as 
SD-33_Z(OMe)-Gly-PA was obtained from Z(OMe)- 
Gly and phenethylamine by condensing with NDPP in 
85%yield (m.p. 124-125”C;R,’ 0.93; satisfactory 
analysis for C19H2204N2). 
Boc-Tyr-D-Met(O)-Gly-PA was obtained from 
Boc-Tyr-D-Met(O)-N2Hs and Gly-PA (deblocked 
from Z(OMe)-Gly-PA with TFA-anisole) by the 
azide method in 78% yield (m.p. 112-l 15’C;RF’ 
0.74; satisfactory analysis for C29H4007N4S - H20). 
Tyr-D-Met(O)-Gly-PA (SD-32) was obtained 
from the protected tripeptide amide by deblocking 
procedure with TFA as the acetate form in 89% yield 
(m.p. 102-104”C;R,’ 0.22,RF2 0.34;satisfactory 
analysis for C24H3205N4S . CHJC02H - 1.5 H20). 
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2.2. Bioassay 
Biological activities were examined as in [ Ill. The 
opioid activity was determined in vitro by inhibition 
of electrically evoked contraction of the isolated 
guinea pig ileum [ 141. Analgesia following S.C. admin- 
istration was estimated in the tail flick [ 15,161 and 
phenylquinone writhing [ 16,171 tests in mice. 
3. Results and discussion 
The in vitro and in vivo opiate agonist activities are 
summarized in table 1. Both Tyr-D-Met(O)-Gly-PA 
In the tail-flick test after S.C. administration, 
(SD-32) and SD-33 showed a potent in vitro opioid 
SD-32 was <5% as potent as morphine, but N-meth- 
ylation of phenethylamide caused a remarkable 
activity in the guinea pig ileum assay. Their activities 
increase in potency; SD-33 exhibited analgesic activ- 
ity nearly comparable to that of morphine. A similar 
were reversed by naloxone. 
Morphine *HCl 
I I I 1 I I I 
0 30 60 90 120 150 180 
Time (min) after drug injection 
Fig.2. Time-course of analgesic activity of SD-33 and morphine in the tail flick test in mice: ( ) dose in mg/kg, sub-cutaneously; 
* 0.01 <P < 0.05; ** P < 0.01 different from each pre-drug value. Each point and vertical bar represent he mean and SEM from 
10 mice. 
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phenomenon was observed for potential increase in 
the case of SD-25 which was obtained by the N-meth- 
ylation of phenylalaninol in SD-20 [ 111. The analgesic 
effect of SD-33 was relatively durable; EDW values 
were 4.15,7.02 and 5.44 mg/kg (n = 30) at 0.5, 1 and 
1.5 h, respectively, after S.C. administration, and those 
of morphine were 2.9,2.7 and 4.6 mg/kg (n = 30) at 
0.5, 1 and 1.5 h, respectively (fig.2). The effect of 
SD-33, like that of morphine, was reversed by nalox- 
one. It was surprising that a simple tripeptide alkyla- 
mide, such as SD-33, exhibited such a potent analgesic 
activity after S.C. administration. 
In the writhing test after S.C. administration, SD-33 
and SD-32 were in agreement with the results in the 
tail-flick test. The potency of SD-33 was nearly com- 
parable to that of morphine, while SD-32 was <lo% 
as potent as morphine. 
For the first time, a tripeptide alkylamide has been 
prepared which exhibits substantial analgesia after S.C. 
administration and SD-33 may be the ‘minimal seg- 
ment’ of an opioid peptide required for S.C. analgesia, 
although structurally it bears little resemblance any 
longer to enkephalin. The stability in vitro and in vivo, 
the ready availability and high melting point 
(140-144’C) should make it valuable for further 
studies on opioid peptides. 
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